Skip to content

Author

F. Ciardiello

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Favezelimab/Pembrolizumab Coformulation Versus Standard-of-Care in PD-L1–Positive Metastatic Colorectal Cancer: The Phase III, Randomized KEYFORM-007 Study

The phase III KEYFORM-007 study (ClinicalTrials.gov identifier: NCT05064059 ) evaluated the efficacy and safety of coformulated favezelimab/pembrolizumab versus standard-of-care (SOC) in PD-L1–positive microsatellite stable/mismatch repair proficient (MSS/pMMR) metastatic colorectal cancer (mCRC). We present re...

N. Segal, Maria Passhak, F. Kose et al. · 0 citations
Open access Oct 2026

NK cell immune fitness stratifies small cell lung cancer into four functional states associated with clinical response

The reasons why some patients with small-cell lung cancer (SCLC) benefit from chemotherapy and immunotherapy, while others rapidly develop resistance, are still undefined. Despite improved outcomes with platinum-based chemotherapy combined with immune checkpoint inhibitors have been correlated to activation of the inna...

C. De Rosa, Fabio Somma, Luisa Amato et al. · 0 citations
Open access Sep 2026

Circulating tumor DNA tumor fraction as a biomarker in refractory metastatic colorectal cancer: findings from the CAVE-2 GOIM trial

Liquid biopsy guided anti-EGFR rechallenge therapy is gaining ground as a potential option for patient with refractory metastatic colorectal cancer. However, the identification of potential biomarkers to implement patient's stratification is required. The CAVE-2 GOIM trial investigated the role of rechallenge with cetu...

Davide Ciardiello, G. Martini, L. Boscolo Bielo et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.